INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Inhibrx Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$89.79−0.04 (-0.04%)
Close on Oct 19, 2026
- Market cap
- $1.41B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$52.54 (+141.0%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Inhibrx Biosciences, Inc. grew revenue 550.0% to $1.30M over fiscal 2025. Free cash flow was -$131.90M.
Revenue
$1.30M
+550.0% vs. a year earlier
Operating income
-$127.81M
TTM Q2 2026
Free cash flow
-$131.90M
TTM Q2 2026
EPS, diluted
-$8.88
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $1.41B
- P/E ratio
- –
- Price to sales
- 1082.25
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -9.38%
Fundamentals
- Revenue
- $1.30M
- Net income
- -$138.18M
- EPS, diluted
- -$8.88
- Free cash flow
- -$131.90M
- Book value per share
- -$3.38
- Diluted shares
- 16M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$127.81M
Net income
-$138.18M
EPS, diluted
-$8.88
Free cash flow
-$131.90M
Reported periodTrailing twelve months